Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $5.7950 (-15.09%) ($5.7950 - $5.7950) on Tue. Sep. 6, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.95% (three month average) | RSI | 33 | Latest Price | $5.7950(-15.09%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.3% a day on average for past five trading days. | Weekly Trend | TGTX declines -3.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) IYT(89%) PCY(88%) IPO(96%) SKYY(84%) IBB(83%) | Factors Impacting TGTX price | TGTX will decline at least -3.475% in a week (0% probabilities). USO(-37%) OIH(-9%) EMHY(48%) TBT(-94%) UUP(-63%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.475% (StdDev 6.95%) | Hourly BBV | -1.6 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.22 | 5 Day Moving Average | $6.78(-14.53%) | 10 Day Moving Average | $6.9(-16.01%) | 20 Day Moving Average | $7.22(-19.74%) | To recent high | -31.2% | To recent low | 55.2% | Market Cap | $734m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |